We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Huge COVID-19 Testing Demand to Drive Global Point-of-Care Diagnostics Market to USD 11.7 Billion by 2024

By LabMedica International staff writers
Posted on 01 Oct 2020
The global point-of-care diagnostics market stood at USD 6.8 billion in 2016 and is expected to register a stellar CAGR of 6.9% to reach USD 11.7 billion by the end of 2024, driven mainly by the rise in COVID-19 testing. More...
Other factors supporting the growth of the point-of-care diagnostics market are the increased prevalence of infectious diseases such as tuberculosis, AIDS, etc. and the rising incidences of target conditions. The increasing demand for rapid diagnostics among the general populace is also assisting the growth of the point-of-care diagnostics market.

These are the latest findings of Transparency Market Research (Albany NY, USA), a market research company.

The need for making the healthcare sector more patient-centric is proving to be beneficial for the increase in the growth rate of the point-of-care diagnostics market. The centralized testing process does not seem convenient for many patients as it involves frequent visits to the clinics to complete the entire assessment process. Point-of-care devices offer a much-needed helping hand for achieving the goal of a patient-centric approach. As a result, the point-of-care diagnostics market is likely to experience a considerable spike in its growth rate during the forecast period.

The COVID-19 outbreak has prompted a fierce demand for point-of-care diagnostics kits. As of now, no vaccine is available for controlling the deadly disease. Maximum testing and quick hospitalization are key components for flattening the curve. The point-of-care diagnostics devices form the crux of increased testing. Manufacturers in the point-of-care diagnostics market are focusing on developing novel technologies for maximum testing within a minimum period. The use of cutting-edge technologies enables the point-of-care diagnostic kits to target RdRp genes for detecting positive cases in as little as five minutes. CRISPR-based technologies are also helping generate growth for the point-of-care diagnostics market to a great extent. The novel coronavirus has accelerated research and development activities in the point-of-care diagnostics market. Development and production in maximum numbers is the need of the hour. Therefore, quick FDA approvals are fueling the growth of the point-of-care diagnostics market.

Given the rising threat of SARS-CoV-2 transmission, the influx of patients to the clinics is likely to decline significantly. Thus, home care may gain considerable traction even after the lockdown. Eventually, smartphone-based point-of-care diagnostics is estimated to propel the market growth. Innovations such as smartphones combined with a microfluidic chip for rapid testing results could generate tremendous growth opportunities for the point-of-care diagnostics market. Home-based glucose monitoring systems are also garnering good sales due to the launch of innovative and advanced monitoring technologies such as well as the frequent multiplication of diabetes cases across the world. Also, patients with co-morbidities are more prone to fatality caused due to COVID-19. Hence, these devices provide efficient diagnostics at home without feeling the need for a visit to the clinic for consultation.

The major players are betting heavily on the growth of the point-of-care diagnostics market through investments, mergers, acquisitions, joint ventures, and partnerships. An increase in medical and surgical procedures, coupled with the advancement of new technologies, makes the point-of-care diagnostics market a profitable option for investment. The soaring demand for point-of-care diagnostics is likely to boost the scale of investments in the market. Major players involved in the point-of-care diagnostics market are always engaged in discovering efficient and path-breaking products. Further, the adoption of various technologies such as ultrasounds can also aid the growth of the point-of-care diagnostics market.

Geographically, North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America are the major regional segments of the global point-of-care diagnostics market. North America will continue to lead the global point-of-care diagnostics market due to early access to the availability of new technologies and advanced healthcare infrastructure in the region. Rising cases of diabetes in the US is likely to support the growth of the North American point-of-care diagnostics market. Additionally, mini-growth enhancers such as technology miniaturization, improved portability, and lower system cost will further benefit the point-of-care diagnostics market in North America.

Related Links:
Transparency Market Research


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.